About Biologic Medicines

At Juno, our goal is twofold: increase patient access to high quality, lifesaving medicines and increase value within the Australian healthcare system.

Biosimilars and interchangeable biologic products present an opportunity to patients, healthcare professionals and the government, by providing increased patient access to therapies, whilst helping maintain the long-term viability and financial sustainability of the Australian and New Zealand healthcare systems.

We believe that we have the right expertise and strategies to effectively partner with biologic developers whose brands are reaching their patent expiry, plus biosimilar developers with plans to launch in Australia and New Zealand.

 

Development And Approval Process

Biosimilar medicine development is target-orientated, comparative, and follows a stepwise approach9,13,14. Highly sophisticated analytical tools allow for a detailed characterisation of the biosimilar medicine and the reference product13,14. Due to technological advances, biosimilar medicines are usually better characterised than their reference products, which were characterised at the time of their initial approval 10 or 20 years earlier5,15.

The pillars of a biosimilar product development and marketing approval: